Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by Laconchapon Jan 14, 2021 12:28am
217 Views
Post# 32291860

Year over Year (YoY). Labs look good

Year over Year (YoY). Labs look goodHealth Care: BioTech, Big Pharma Set to Enjoy COVID Boost Projected Q4 EPS Growth: +6.6% YoY Projected Q4 Revenue Growth: +10% YoY The Health Care sector is set to enjoy tailwinds from the race to deliver successful COVID-19 vaccines and treatments, as it is expected to report the second-highest YoY earnings growth of all eleven sectors. EPS is projected to rise 6.6% compared to a year earlier.
<< Previous
Bullboard Posts
Next >>